Published in Gastroenterology on November 01, 1985
Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg (2006) 4.30
Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia (2004) 1.83
Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metab (2010) 1.71
Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut (1987) 1.68
Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut (1999) 1.66
Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' to gastric emptying. Gut (1996) 1.60
Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann Surg (2009) 1.47
Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci (2006) 1.47
Gut regulatory peptides and intestinal permeability in acute infantile gastroenteritis. Arch Dis Child (1992) 1.46
The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun (2014) 1.44
The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol (2011) 1.40
PYY-Dependent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass Surgery. Cell Rep (2016) 1.39
The role of peptide YY in appetite regulation and obesity. J Physiol (2008) 1.32
Beta glucan: health benefits in obesity and metabolic syndrome. J Nutr Metab (2011) 1.24
Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol (2010) 1.23
Human pancreatic exocrine response to nutrients in health and disease. Gut (2005) 1.16
Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. Gut Liver (2012) 1.16
Lack of association between impaired glucose tolerance and appetite regulating hormones in patients with obstructive sleep apnea. J Clin Sleep Med (2011) 1.14
Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone (2008) 1.13
Gene-environment interactions controlling energy and glucose homeostasis and the developmental origins of obesity. Physiol Rev (2015) 1.10
Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut (2000) 1.08
Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut (1993) 1.07
Changes in appetite related gut hormones in intensive care unit patients: a pilot cohort study. Crit Care (2006) 1.05
Obesity and appetite control. Exp Diabetes Res (2012) 1.05
Effects of meals high in carbohydrate, protein, and fat on ghrelin and peptide YY secretion in prepubertal children. J Clin Endocrinol Metab (2009) 1.05
Obesity, gut hormones, and bariatric surgery. World J Surg (2009) 1.04
The use of the reinstatement model to study relapse to palatable food seeking during dieting. Neuropharmacology (2013) 1.04
The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes (Lond) (2014) 1.03
Peptides and food intake. Front Endocrinol (Lausanne) (2014) 1.01
Peptides and their potential role in the treatment of diabetes and obesity. Rev Diabet Stud (2011) 1.01
Plasma peptide YY and ghrelin levels in infants and children with Prader-Willi syndrome. J Pediatr Endocrinol Metab (2004) 0.98
Proliferative effects of 'fibre' on the intestinal epithelium: relationship to gastrin, enteroglucagon and PYY. Gut (1987) 0.98
Appetite-regulating hormones cortisol and peptide YY are associated with disordered eating psychopathology, independent of body mass index. Eur J Endocrinol (2010) 0.97
Molecular mechanisms of appetite regulation. Diabetes Metab J (2012) 0.97
Bench-to-bedside review: the gut as an endocrine organ in the critically ill. Crit Care (2010) 0.96
Anorexia induction by the trichothecene deoxynivalenol (vomitoxin) is mediated by the release of the gut satiety hormone peptide YY. Toxicol Sci (2012) 0.95
Characterization of the diurnal rhythm of peptide YY and its association with energy balance parameters in normal-weight premenopausal women. Am J Physiol Endocrinol Metab (2011) 0.95
Obesity treatment: novel peripheral targets. Br J Clin Pharmacol (2009) 0.95
Minireview: Gut peptides: targets for antiobesity drug development? Endocrinology (2009) 0.94
Intestinal feedback signaling and satiety. Physiol Behav (2011) 0.94
Long-term exercise training in overweight adolescents improves plasma peptide YY and resistin. Obesity (Silver Spring) (2009) 0.94
Role of Gut-Related Peptides and Other Hormones in the Amelioration of Type 2 Diabetes after Roux-en-Y Gastric Bypass Surgery. ISRN Endocrinol (2012) 0.94
The paradox of the pouch: prompt emptying predicts improved weight loss after laparoscopic Roux-Y gastric bypass. Surg Endosc (2008) 0.94
Neuropeptide Y Y2 receptor in health and disease. Br J Pharmacol (2007) 0.93
PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes (2010) 0.92
Variations in peptide YY and Y2 receptor genes are associated with severe obesity in Pima Indian men. Diabetes (2005) 0.92
Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. JPEN J Parenter Enteral Nutr (2011) 0.91
Gastric stimulation for weight loss. World J Gastroenterol (2012) 0.91
Influence of running and walking on hormonal regulators of appetite in women. J Obes (2012) 0.91
Increased carbohydrate induced ghrelin secretion in obese vs. normal-weight adolescent girls. Obesity (Silver Spring) (2009) 0.91
Gut and mind. Gut (2003) 0.90
Leptin extends the anorectic effects of chronic PYY(3-36) administration in ad libitum-fed rats. Am J Physiol Regul Integr Comp Physiol (2008) 0.90
Denatonium induces secretion of glucagon-like peptide-1 through activation of bitter taste receptor pathways. Diabetologia (2014) 0.89
The gut hormones in appetite regulation. J Obes (2011) 0.88
Appetite regulation and weight control: the role of gut hormones. Nutr Diabetes (2012) 0.88
Obese adolescents show impaired meal responses of the appetite-regulating hormones ghrelin and PYY. Obesity (Silver Spring) (2010) 0.88
Xenin, a gastrointestinal peptide, regulates feeding independent of the melanocortin signaling pathway. Diabetes (2008) 0.87
Gut hormones in adaptation. Gut (1987) 0.87
Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass. Osteoporos Int (2013) 0.87
Axon-like basal processes in enteroendocrine cells: characteristics and potential targets. Clin Transl Sci (2011) 0.86
Cholinergic regulation of ghrelin and peptide YY release may be impaired in obesity. Diabetes (2008) 0.86
The role of viscosity and fermentability of dietary fibers on satiety- and adiposity-related hormones in rats. Nutrients (2013) 0.85
Intramural distribution of regulatory peptides in the sigmoid-recto-anal region of the human gut. Gut (1988) 0.84
Carbohydrate-rich breakfast attenuates glycaemic, insulinaemic and ghrelin response to ad libitum lunch relative to morning fasting in lean adults. Br J Nutr (2015) 0.84
The multiple faces of glucagon-like peptide-1--obesity, appetite, and stress: what is next? A review. Dig Dis Sci (2007) 0.84
The TRPA1 agonist, methyl syringate suppresses food intake and gastric emptying. PLoS One (2013) 0.84
Obesity pharmacotherapy: what is next? Mol Aspects Med (2012) 0.84
Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction. Surg Endosc (2011) 0.84
Differential effects of two fermentable carbohydrates on central appetite regulation and body composition. PLoS One (2012) 0.84
Responses of python gastrointestinal regulatory peptides to feeding. Proc Natl Acad Sci U S A (2001) 0.83
Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein. J Clin Invest (1990) 0.83
Effects of endurance running and dietary fat on circulating ghrelin and peptide YY. J Sports Sci Med (2009) 0.83
Therapy for obesity based on gastrointestinal hormones. Rev Diabet Stud (2011) 0.83
Bile salt inhibition of motility in the isolated perfused rabbit terminal ileum. Gut (1993) 0.83
Physiogenomic comparison of human fat loss in response to diets restrictive of carbohydrate or fat. Nutr Metab (Lond) (2008) 0.83
L-cysteine suppresses ghrelin and reduces appetite in rodents and humans. Int J Obes (Lond) (2014) 0.83
PYY(1-36) is the major form of PYY in rat distal small intestine: quantification using high-resolution mass spectrometry. Regul Pept (2010) 0.82
Intestinal transit is more potently inhibited by fat in the distal (ileal brake) than in the proximal (jejunal brake) gut. Dig Dis Sci (1997) 0.82
Pathways and receptors involved in peptide YY induced contraction of rat proximal colonic muscle in vitro. Gut (2000) 0.82
Suggestion of new possibilities in approaching individual variability in appetite through constitutional typology: a pilot study. BMC Complement Altern Med (2012) 0.82
Short-term aerobic exercise training increases postprandial pancreatic polypeptide but not peptide YY concentrations in obese individuals. Int J Obes (Lond) (2013) 0.82
Hormonal regulators of appetite. Int J Pediatr Endocrinol (2008) 0.81
Can Bayliss and Starling gut hormones cure a worldwide pandemic? J Physiol (2014) 0.81
Ghrelin and PYY levels in adolescents with severe obesity: effects of weight loss induced by long-term exercise training and modified food habits. Eur J Appl Physiol (2011) 0.81
Ghrelin and peptide YY in postpartum lactating and nonlactating women. Am J Clin Nutr (2009) 0.80
Peptide YY: more than just an appetite regulator. Diabetologia (2014) 0.80
Leptin secretory dynamics and associated disordered eating psychopathology across the weight spectrum. Eur J Endocrinol (2016) 0.80
Metabolic surgery-principles and current concepts. Langenbecks Arch Surg (2011) 0.80
A role for endogenous peptide YY in tachykinin NK(2) receptor-triggered 5-HT release from guinea pig isolated colonic mucosa. Br J Pharmacol (2012) 0.80
Colonic responses to enteral tube feeding. Gut (1998) 0.80
Regulation of hindbrain Pyy expression by acute food deprivation, prolonged caloric restriction, and weight loss surgery in mice. Am J Physiol Endocrinol Metab (2012) 0.80
Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence? Int J Obes (Lond) (2015) 0.79
The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs. BMC Res Notes (2016) 0.79
Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones. Int J Colorectal Dis (2007) 0.79
The relationship between gastric emptying, plasma cholecystokinin, and peptide YY in critically ill patients. Crit Care (2007) 0.79
Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature (1998) 7.36
Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab (2001) 6.41
A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996) 6.03
Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet (1987) 4.97
The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology (2000) 3.80
Ghrelin causes hyperphagia and obesity in rats. Diabetes (2001) 3.62
A glucagonoma syndrome. Lancet (1974) 3.56
Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology (2001) 3.38
Vasoactive intestinal peptide and watery-diarrhoea syndrome. Lancet (1973) 3.22
Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation (2001) 3.18
Possible dual role for vasoactive intestinal peptide as gastrointestinal hormone and neurotransmitter substance. Lancet (1976) 3.08
Distribution and release of human pancreatic polypeptide. Gut (1976) 3.02
Induction of nitric oxide synthase in asthma. Lancet (1994) 2.93
Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology (2005) 2.80
Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut (1971) 2.75
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet (1974) 2.65
Neuron-specific enolase is produced by neuroendocrine tumours. Lancet (1981) 2.63
Breast vs bottle: endocrine responses are different with formula feeding. Lancet (1980) 2.52
Measurement of fasting and postprandial plasma VIP in man. Gut (1978) 2.48
Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest (1999) 2.48
Precursor cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. Development (1993) 2.41
Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycaemia. Arch Dis Child (1981) 2.36
Improved section adhesion for immunocytochemistry using high molecular weight polymers of L-lysine as a slide coating. Histochemistry (1983) 2.35
Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein synthesis. Biochem Biophys Res Commun (2000) 2.28
Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis. J Neuroendocrinol (2004) 2.27
Gut-hormone profile in coeliac disease. Lancet (1978) 2.25
Saturation of fat and cholecystokinin release: implications for pancreatic carcinogenesis. Lancet (1989) 2.25
Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol (2001) 2.24
Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5 dissolution. J Biomed Mater Res (2001) 2.24
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab (2001) 2.24
Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol (2001) 2.20
Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem Biophys Res Commun (1979) 2.16
Gut hormones and appetite control. Gastroenterology (2007) 2.16
A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology (1998) 2.14
Pancreatic polypeptide in insulinomas, gastrinomas, vipomas, and glucagonomas. Lancet (1976) 2.13
Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med (1990) 2.12
The ileal brake--inhibition of jejunal motility after ileal fat perfusion in man. Gut (1984) 2.11
Neuropeptide Y distribution in the rat brain. Science (1983) 2.10
Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet (1975) 2.04
The role of the sympathetic innervation in the control of plasma glucagon concentration in the calf. J Physiol (1973) 2.01
Differentiation of osteoblasts and in vitro bone formation from murine embryonic stem cells. Tissue Eng (2001) 1.97
Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun (1994) 1.96
Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment. Thorax (2001) 1.95
Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet (1996) 1.95
Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br Med J (Clin Res Ed) (1983) 1.93
Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg (2006) 1.91
Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes (1999) 1.90
Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest (1997) 1.89
Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species. J Neurosci (1984) 1.88
Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet (1992) 1.88
Effects of stimulation of the chorda tympani in bursts on submaxillary responses in the cat. J Physiol (1982) 1.84
The genesis of apudamyloid in endocrine polypeptide tumours: histochemical distinction from immunamyloid. Virchows Arch B Cell Pathol (1972) 1.83
Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue. Lancet (1979) 1.81
Bifunctional reagents as vapour- and liquid-phase fixatives for immunohistochemistry. Histochem J (1975) 1.80
Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice. Heterogeneity of hormone expression. Am J Pathol (1990) 1.80
Increased leptin levels in serum and peritoneal fluid of patients with pelvic endometriosis. J Clin Endocrinol Metab (2000) 1.75
Enkephalin-like immunoreactivity in the human gastrointestinal tract. Lancet (1977) 1.75
Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology (1997) 1.74
Localization of atrial natriuretic peptide mRNA and immunoreactivity in the rat heart and human atrial appendage. Proc Natl Acad Sci U S A (1987) 1.74
The effect of truncal and selective vagotomy on the release of pancreatic glucagon, insulin and enteroglucagon. Br J Surg (1974) 1.73
Immunofluorescent localization of secretin in the canine duodenum. Gut (1971) 1.73
Bombesin-like immunoreactivity in the lung. Nature (1978) 1.73
Localization of insulinomas by selective intraarterial calcium injection. J Clin Endocrinol Metab (1996) 1.72
Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet (1974) 1.71
Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab (2003) 1.71
Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease. Gastroenterology (1980) 1.70
Bromocriptine treatment of acromegaly. Br Med J (1975) 1.70
A neurogenic mechanism for symmetrical arthritis. Lancet (1989) 1.69
An enteroglucagon tumour. Gut (1972) 1.69
Free radical scavengers prevent reflux esophagitis in rats. Dig Dis Sci (1995) 1.69
Bioglass 45S5 stimulates osteoblast turnover and enhances bone formation In vitro: implications and applications for bone tissue engineering. Calcif Tissue Int (2000) 1.68
Mechanism of pancreatic polypeptide release in man. Lancet (1977) 1.68
Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut (1987) 1.68
A morphological and immunocytochemical study of a distinctive variant of ductal carcinoma in-situ of the breast. Histopathology (1985) 1.67
Motilin and the interdigestive migrating motor complex in man. Dig Dis Sci (1979) 1.67
The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol (1988) 1.67
A radioimmunoassay for neurotensin in human plasma. J Endocrinol (1979) 1.66
Neuropeptide Y distribution in human brain. Nature (1984) 1.66